Indian CDMO Sector: Strong Q1 FY27, Rising Margins and Bigger Capacity Bets
The Indian CDMO sector enters FY27 on a strong note, with healthy Q1 growth, improving margins and rising investments in manufacturing capacity. Here’s what investors should watch.
By IPO Master
Indian CDMO Sector: Strong Q1 FY27, Rising Margins and Bigger Capacity Bets
The Indian Contract Development and Manufacturing Organisation (CDMO) sector has started FY27 on a strong note. Several leading companies reported healthy revenue and profit growth in Q1 FY27, while many are also increasing investments in new manufacturing capacity.
The bigger opportunity comes from global pharma companies looking to diversify their supply chains and outsource more specialised manufacturing to India.
However, investors should remember that CDMO earnings can be uneven because revenues often depend on project execution, customer orders and delivery schedules.
1. Why Is the Indian CDMO Sector Growing?
There are several factors supporting the long-term growth of Indian CDMO companies.
1. China+1 Strategy
Global pharmaceutical companies are reducing their dependence on China and diversifying their manufacturing supply chains.
India is emerging as an important alternative because of its:
Skilled workforce
Manufacturing capabilities
Cost competitiveness
Growing pharmaceutical ecosystem
This could create more opportunities for Indian CDMO companies.
2. Increasing Pharma Outsourcing
Large pharmaceutical companies are increasingly outsourcing drug development and manufacturing activities to specialised CDMO companies.
This allows pharma companies to reduce manufacturing costs and focus more on research, marketing and commercialisation.
3. Patent Expiries
As several pharmaceutical products lose patent protection, new manufacturing opportunities are emerging.
Indian CDMOs with strong technical capabilities can benefit from this growing demand.
4. Growth in New Therapies
New-generation therapies such as peptides, ADCs and biologics require specialised manufacturing capabilities.
This creates an opportunity for Indian companies to move from traditional manufacturing towards higher-value services.
2. Q1 FY27 Performance of Major CDMO Companies
The Q1 FY27 results of several companies show the strength of the sector.
Laurus Labs
Laurus Labs delivered strong growth during the quarter.
CDMO revenue: ₹835 crore
CDMO revenue growth: 69% YoY
Overall revenue growth: 29%
Net profit growth: 125%
FY27 capex guidance: ₹2,000 crore
The increase in capex indicates that the company expects demand to remain strong and is preparing for future growth.
Divi's Laboratories
Divi's Laboratories also reported healthy growth.
Revenue growth: 28%
PAT growth: around 66%
Custom synthesis contribution: around 60% of revenue
The increasing contribution from custom synthesis is important because it reflects the company's growing exposure to higher-value CDMO activities.
Navin Fluorine
Navin Fluorine delivered another strong quarter.
Revenue growth: 44%
PAT growth: 108%
The improvement was supported by:
Better product mix
Higher realisations
Improved plant utilisation
The numbers indicate strong operational improvement during the quarter.
Neuland Laboratories
Neuland Laboratories was among the strongest performers.
Revenue growth: 119% YoY
Net profit: nearly 10x growth
The performance was primarily supported by large commercial manufacturing projects moving into the execution phase.
This also highlights an important characteristic of the CDMO industry: large projects can create significant changes in quarterly financial performance.
OneSource Specialty Pharma
OneSource Specialty Pharma benefited from increasing demand related to the GLP-1 opportunity.
Revenue growth: 37%
Strong demand for semaglutide-related manufacturing
High utilisation in sterile injectables capacity
The growing demand for GLP-1-related products could become an important opportunity for specialised pharmaceutical manufacturers.
3. Not Every Company Delivered Strong Growth
While several companies reported impressive numbers, the sector is not without challenges.
Anthem Biosciences
Anthem Biosciences reported:
Revenue decline: 23%
Margins improved
According to the information provided, the weakness was largely linked to delivery timing, with a significant portion of the order book expected to be executed in H2 FY27.
This shows why investors should avoid judging a CDMO company purely on one quarter.
Piramal Pharma
Piramal Pharma's CDMO business reported:
CDMO revenue growth: 19%
EBITDA growth: 72%
However, high depreciation and finance costs continued to affect the company's consolidated profitability.
4. What Do These Results Tell Investors?
The Q1 FY27 results provide an important lesson:
A weak quarter does not always mean weak demand.
Similarly,
A very strong quarter does not guarantee that the same growth rate will continue.
CDMO businesses are often dependent on:
Customer orders
Project execution
Product launches
Manufacturing timelines
Capacity utilisation
Delivery schedules
Therefore, investors should focus on the long-term trend rather than one quarterly number.
5. Six Things Investors Should Watch
Before evaluating a CDMO company, investors can focus on these six factors.
1. Margins
Are margins improving because the company is moving towards higher-value products and services?
2. Order Book
How much future business has already been secured?
A strong order book can provide better revenue visibility.
3. Capacity Utilisation
New factories and manufacturing facilities are useful only when they generate meaningful revenue.
Investors should therefore track how quickly new capacity is being utilised.
4. Working Capital
Revenue growth should ideally translate into stronger cash generation.
High receivables or excessive working-capital requirements can reduce the quality of reported growth.
5. Customer Concentration
Investors should understand how dependent a company is on a few large customers.
Greater customer diversification can reduce business risk.
6. Capex Discipline
Companies are investing heavily in new manufacturing capacity.
The important question is:
Is the company investing based on visible demand or simply on future expectations?
6. India's CDMO Capex Cycle
The Indian CDMO industry is entering a significant capacity expansion phase.
Companies including:
Laurus Labs
SAI Life Sciences
Anthem Biosciences
Neuland Laboratories
are investing in new facilities and specialised manufacturing capabilities.
The success of this investment cycle will depend on how quickly new capacity gets utilised and starts generating attractive returns.
7. Why the Next Few Years Could Be Important
The long-term opportunity for Indian CDMOs remains attractive because several structural trends are working together.
Global pharma outsourcing + China+1 + complex therapies + specialised manufacturing = growing opportunity for Indian CDMOs.
However, simply having large capacity will not be enough.
Companies will need:
Strong customer relationships
High-quality manufacturing capabilities
Better margins
Healthy order visibility
Efficient capacity utilisation
Disciplined capital allocation
8. The Key Question for Investors
The Q1 FY27 results suggest that the Indian CDMO sector has strong growth potential.
But investors should look beyond headline revenue and profit numbers.
The most important question is:
Is the company's order book, capacity and profitability all moving in the same direction?
If the answer is yes, the company may be better positioned to benefit from the long-term CDMO opportunity.
If revenue is growing but capacity utilisation, cash flow or margins are weakening, investors may need to look deeper.
9. Bottom Line
The Indian CDMO sector has started FY27 with encouraging numbers.
Companies such as Laurus Labs, Divi's Laboratories, Navin Fluorine, Neuland Laboratories and OneSource Specialty Pharma demonstrated strong growth, while the sector continues to benefit from global outsourcing and the China+1 strategy.
At the same time, quarterly volatility remains a key characteristic of the industry.
For investors, the focus should therefore remain on execution, margins, order visibility, capacity utilisation, cash flow and capital allocation rather than simply looking at one quarter's growth.
Key Takeaway
India's CDMO opportunity looks strong, but execution will determine which companies ultimately create sustainable shareholder value.
Use the list on the right to open the next post.